triple glp-1/gip/glucagon receptor agonist retatrutide glp-1 gip glucagon Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight LY3437943, a novel triple glucagon,

4,5 TABLE 1 provides a summary of key characteristics of currently available injectable GLP-1 receptor agonists

Future RCTs that are larger and longer-term, along with real-world studies that appropriately involve diverse ethnic groups, are anticipated to enhance our understanding of the oncogenic or anti-oncogenic potential (if any) of tirzepatide

Protein supplementation during GLP-1 treatment can further support muscle preservation

Its easy to feel like progress is just out of reach, like you're on a treadmill, running hard but not getting anywhere

Clin Case Rep

These medications carry an FDA boxed warning for medullary thyroid carcinoma and are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2